Feb09Tue

Member News from ICON Clinical Research

ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases

ICON selected as Data Management Partner for the 100,000 Genomes Project

Dublin, Ireland, 9th February, 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.

A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS) cancer and rare disease patients and their families. It aims to demonstrate a new genomic medicine service for the NHS to support better diagnosis and more personalised treatments for patients. De-identified data from the 100,000 Genomes Project will also be made available to approved researchers from industry to help accelerate the development of new treatments and diagnostic tests that are targeted at the genetic characteristics of individual patients.

Read More

Dec21Mon

Global Economic Forum 2016

IABCN Founder & Chairman Emeritus, Bill McLaughlin, participated in the 2016 Global Irish Economic Forum last month, the fourth such forum.

While previous Forums concentrated on recovery from the financial crisis, and rebuilding Ireland’s reputation internationally, this year the overarching theme was on sustaining and strengthening our robust economic growth into the future, with a particular focus on opportunities in high-potential sectors including financial services, research and innovation and international education.  It also focused on fostering entrepreneurship and supporting indigenous businesses to scale up, increase exports and create jobs at home. To learn more, please click HERE.

To read the November Global Irish Newsletter, please click HERE.

Bill McLaughlin, IABCN Founder, with Tom Arnold, Director General, Institute of International and European Affairs

Bill McLaughlin, IABCN Founder, with Tom Arnold, Director General, Institute of International and European Affairs

Dec07Mon

Member News from ICON Clinical Research

ICON Acquires PMG Research Inc.

Acquisition enhances ICON’s site and patient engagement capabilities

Dublin, Ireland, 7th December, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PMG Research, Inc., an integrated network of clinical research sites operating from 12 metropolitan areas throughout the US. The acquisition will enhance ICON’s ability to access and engage with investigator sites and patients, helping customers to reduce the overall time and cost associated with drug development. 

Read More